Use of Irbesartan to Maintain Sinus Rhythm in Patients With Long-Lasting Persistent Atrial Fibrillation: A Prospective and Randomized Study

By A. Madrid, M. G. Bueno, J. Rebollo, I. Marín, G. Peña, E. Bernal, Aníbal Rodríguez, L. Cano, J. M. Cano, P. Cabeza and 1 more. Circulation, 2002

731 citations recorded by the source corpus.

Subfields: Cardiology and Cardiovascular Medicine

View Paper: https://www.semanticscholar.org/paper/466af3c3fb45c1c708fa95fdac98f6127cb4cef2

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

J. Kalman
R. Pathak
M. Middeldorp
A. Mehta
R. Mahajan
R. McEvoy
P. Sanders
D. Twomey

Citations in the corpus

2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. (2016, neutral): “reduce recurrent AF after cardioversion when co-administered with antiarrhythmic drug therapy compared with an antiarrhythmic drug alone.(248,249) Meta-analyses driven by these studies suggested a lower risk of recurrent AF, but at least one controlled trial failed to demonstrate benefit.”
ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation-executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committ (2006, neutral): “Angiotensin inhibition may be associated with a reduced incidence of AF in patients with HF (15) and hypertension (16).”
ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation--executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Commit (2006, neutral): “Angiotensin inhibition may be associated with a reduced incidence of AF in patients with HF (15) and hypertension (16).”
Aggressive risk factor reduction study for atrial fibrillation and implications for the outcome of ablation: the ARREST-AF cohort study. (2014, background): “Angiotensin receptor blockade in conjunction with cardioversion reduces the recurrence of AF (37).”